MY THERAPY TOOLS SL

Their core work

My Therapy Tools is a Madrid-based health technology SME that builds software tools for remote rehabilitation of patients with acquired brain injuries (ABI). Their core product is a cloud-based platform that delivers structured tele-rehabilitation exercises to patients at home, reducing the cost of post-injury recovery while maintaining measurable impact on wellbeing. They validated this concept through an EU feasibility grant, then deepened their technical capability by bringing in a dedicated researcher through the SME Innovation Associate programme. The company positions itself at the intersection of clinical rehabilitation protocols and digital delivery infrastructure.

What they specialise in

How they've shifted over time

In 2016–2017, the company was at concept validation stage — using an SME Phase 1 feasibility grant to test whether a telerehabilitation system for ABI patients could be clinically meaningful and commercially viable. By 2018–2019, the focus had shifted from 'does this work?' to 'how do we build and scale it?', with the cloud platform architecture and treatment delivery becoming the explicit technical focus. The use of the Innovation Associate scheme in the second project suggests they recognised a technical or scientific gap in-house and sought to close it by embedding a researcher directly into the company — a sign of a product team moving from prototype toward a deployable product.

The company was moving from proof-of-concept toward a scalable, cloud-hosted rehabilitation product, and was actively pulling in research talent to accelerate that transition — though their H2020 activity ended in 2019 and their current direction is unclear from available data.

How they like to work

My Therapy Tools consistently led their own projects as coordinator, but with zero recorded consortium partners across both grants — a pattern typical of SME instrument Phase 1 awards, which are designed for solo company applications. This means they have no demonstrated track record of collaborative R&D with external research institutions or industry partners within H2020. Any future consortium partner would be working with a company that is experienced at running its own focused product projects, but has not yet operated within a larger collaborative framework.

No consortium partners are recorded across either H2020 project, which reflects the solo-applicant nature of the SME Instrument Phase 1 and Innovation Associate schemes they used. Their collaboration footprint within EU-funded research is effectively zero beyond their own company boundary.

What sets them apart

My Therapy Tools occupies a narrow but clinically specific niche: rehabilitation software purpose-built for acquired brain injury, not generic physiotherapy or wellness apps. This specificity — ABI protocols, remote delivery, cost containment — differentiates them from broad digital health platforms and from hospital-based rehabilitation providers. For a consortium building a digital health or neurorehabilitation project, they bring a working prototype and clinical domain knowledge in a space where most participants are either pure researchers or large hospital systems with no product-development experience.

Highlights from their portfolio

• MyTherapyTools
  Their 2016–2017 SME Phase 1 grant was the founding proof-of-concept for the entire product — the first EU validation that their ABI telerehabilitation approach was technically and commercially feasible.
• MyTherapyTools
  The 2018–2019 SME Innovation Associate award is notable because it represents a deliberate strategy to embed research expertise inside a small commercial team — an unusual and sophisticated use of EU instruments for a two-person-scale SME.